Names like Amgen, Inc. (NASDAQ:AMGN) and CEL-SCI Corporation (NYSEMKT:CVM) may have pioneered and even mainstreamed the idea of cancer immunology, but the nature of the branch of biotechnology means any company could send CEL-SCI or Amgen back-pedaling. See, it's not about size or deep pockets in the world of biotech anymore. It's about know-how and an idea, which can just as easily be discovered and developed by a small company as they can be a large company. That's why AMGN and CVM at least need to keep a close eye on budding immunology competitor TNI Biotech Inc. (OTCMKTS:TNIB).
OK, CEL-SCI and Amgen don't need to cower in the corner just yet, as there's nothing in their immunology portfolios or pipelines that will be competing head-on with the therapies that TNI Biotech are developing... at least not too soon. Amgen's big foray into the world of immunology is with a melanoma drug, and CEL-SCI is limiting the focus of its Multikine therapy to head and neck cancers. Meanwhile, TNI's immunology biotechnology is only taking aim at Crohn's disease and multiple sclerosis in the near-term, with cancer only on the long-term radar (and even then the specific kind of cancer the technology could treat hasn't been clarified). Nevertheless, given that immunology - the improved and increased response of a patient's own immune system - is something of an all-weather and all-purpose approach, if TNIB can successfully treat MS or Crohn's with its immunology know-how, the approach is apt to be an effective cancer fighting agent. That's why CVM and AMGN may want to keep close tabs on the younger competitor.
Top 5 Gas Stocks To Watch For 2015
With all of that being said, the promise of a powerful cancer or MS treatment isn't the reason newcomers may want to wade into a TNI Biotech Inc. position now. No, what's so interesting about this company at this point in time is the fact that TNIB shares have seemingly perked up out of nowhere, for no reason.
As the nearby chart indicates, the buying interest here went from 0 to 60 in practically no time at all. And, the buying effort has clearly unfurled on higher volume. Why? Good question. There's no answer. Regardless of the lack of explanation though, the fact that this little company has attracted so much investor attention of late - far more than it has at any point in the past several months - tells us something is brewing here. What is it? Nobody knows. But, if TNIB follows the same pattern we've seen from other small cap stocks that have also seemingly perked up on no news, odds are good the reason for the new buying now will be revealed in the near future.
Point being, would-be shareholders who were mulling a position in TNI Biotech may want to consider taking on that trade now rather than later. It's been a while since we've heard anything from the company and seen any real movement from the stock, and both are overdue.
You can visit the corporate website here.
No comments:
Post a Comment